FDA expands Revlimid (lenalidomide) indication to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant.-Celgene

Celgene Corporation announced that the FDA has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded indication makes Revlimid the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.

"Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple myeloma patients. However, most patients will still see their disease recur or progress after this treatment," said Philip McCarthy , M.D., Director, Blood and Marrow Transplant Center, Department of Medicine at Roswell Park Cancer Institute . "Lenalidomide maintenance therapy, which has been shown to increase progression-free survival following autologous stem cell transplant in clinical trials can be considered a standard of care for these patients."